APO Research
Talk to an analyst

APO RESEARCH · REPORT

Avastin (Bevacizumab) Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Avastin (Bevacizumab) Biosimilars Market Outlook and Growth Opportunities 2026

30 December 2025218 pages

Choose your research edition.

Industry ResearchAvastin (Bevacizumab) Biosimilars Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Avastin (Bevacizumab) Biosimilars Industry Growth and Trends Forecast to 2032127 pages · $3,450 USDMarket StructureGlobal Avastin (Bevacizumab) Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Avastin (Bevacizumab) Biosimilars Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Avastin (Bevacizumab) Biosimilars Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The global Avastin (Bevacizumab) Biosimilars market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Avastin (Bevacizumab) Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Avastin (Bevacizumab) Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Avastin (Bevacizumab) Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Avastin (Bevacizumab) Biosimilars market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Avastin (Bevacizumab) Biosimilars market include Biocad, Biocon, Cadila Pharmaceuticals, Centus, Dr Reddy's, Genentech, Hetero, Kirin Biologics and MAbxience, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Avastin (Bevacizumab) Biosimilars market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Avastin (Bevacizumab) Biosimilars and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Avastin (Bevacizumab) Biosimilars sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Avastin (Bevacizumab) Biosimilars market size, projected growth trends, production technologies, key applications, and end-use industries.

Avastin (Bevacizumab) Biosimilars Segment by Company

Biocad

Biocon

Cadila Pharmaceuticals

Centus

Dr Reddy's

Genentech

Hetero

Kirin Biologics

MAbxience

PharmaPraxis

PlantForm

Samsung Bioepis

Sartorius

Amgen

BeiGene

Bayer

TOT BIOPHARM

Henlius

Pfizer

Eli Lilly

Roche

Luye Pharmaceutical

Mylan

Qilu Pharmaceutical

Innovent

Avastin (Bevacizumab) Biosimilars Segment by Type

Cancers

AMD

Avastin (Bevacizumab) Biosimilars Segment by Application

Hospitals

Clinics

Others

Avastin (Bevacizumab) Biosimilars Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Avastin (Bevacizumab) Biosimilars status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Avastin (Bevacizumab) Biosimilars market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Avastin (Bevacizumab) Biosimilars significant trends, drivers, influence factors in global and regions.

6. To analyze Avastin (Bevacizumab) Biosimilars competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Avastin (Bevacizumab) Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Avastin (Bevacizumab) Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Avastin (Bevacizumab) Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Avastin (Bevacizumab) Biosimilars market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Avastin (Bevacizumab) Biosimilars industry.

Chapter 3: Detailed analysis of Avastin (Bevacizumab) Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Avastin (Bevacizumab) Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Avastin (Bevacizumab) Biosimilars in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Avastin (Bevacizumab) Biosimilars Industry Trends Table 2. Avastin (Bevacizumab) Biosimilars Industry Drivers Table 3. Avastin (Bevacizumab) Biosimilars Industry Opportunities and Challenges Table 4. Avastin (Bevacizumab) Biosimilars Industry Restraints Table 5. Global Avastin (Bevacizumab) Biosimilars Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Avastin (Bevacizumab) Biosimilars Revenue Share by Company (2021-2026) Table 7. Global Avastin (Bevacizumab) Biosimilars Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Avastin (Bevacizumab) Biosimilars Sales Volume Share by Company (2021-2026) Table 9. Global Avastin (Bevacizumab) Biosimilars Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Avastin (Bevacizumab) Biosimilars Company Ranking, (2024-2026) & (USD Million) Table 11. Global Avastin (Bevacizumab) Biosimilars Key Company Manufacturing Base & Headquarters Table 12. Global Avastin (Bevacizumab) Biosimilars Company, Product Type & Application Table 13. Global Avastin (Bevacizumab) Biosimilars Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Avastin (Bevacizumab) Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Cancers Table 18. Significant Companies of AMD Table 19. Global Avastin (Bevacizumab) Biosimilars Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Avastin (Bevacizumab) Biosimilars Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Avastin (Bevacizumab) Biosimilars Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Avastin (Bevacizumab) Biosimilars Sales Volume Share by Type (2021-2026) Table 23. Global Avastin (Bevacizumab) Biosimilars Sales Volume Share by Type (2027-2032) Table 24. Global Avastin (Bevacizumab) Biosimilars Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Avastin (Bevacizumab) Biosimilars Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Avastin (Bevacizumab) Biosimilars Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Avastin (Bevacizumab) Biosimilars Sales Value Share by Type (2021-2026) Table 28. Global Avastin (Bevacizumab) Biosimilars Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospitals Table 30. Significant Companies of Clinics Table 31. Significant Companies of Others Table 32. Global Avastin (Bevacizumab) Biosimilars Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Avastin (Bevacizumab) Biosimilars Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Avastin (Bevacizumab) Biosimilars Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Avastin (Bevacizumab) Biosimilars Sales Volume Share by Application (2021-2026) Table 36. Global Avastin (Bevacizumab) Biosimilars Sales Volume Share by Application (2027-2032) Table 37. Global Avastin (Bevacizumab) Biosimilars Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Avastin (Bevacizumab) Biosimilars Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Avastin (Bevacizumab) Biosimilars Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Avastin (Bevacizumab) Biosimilars Sales Value Share by Application (2021-2026) Table 41. Global Avastin (Bevacizumab) Biosimilars Sales Value Share by Application (2027-2032) Table 42. Global Avastin (Bevacizumab) Biosimilars Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Avastin (Bevacizumab) Biosimilars Sales by Region (2021-2026) & (K Units) Table 44. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Region (2021-2026) Table 45. Global Avastin (Bevacizumab) Biosimilars Sales by Region (2027-2032) & (K Units) Table 46. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Region (2027-2032) Table 47. Global Avastin (Bevacizumab) Biosimilars Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Avastin (Bevacizumab) Biosimilars Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Avastin (Bevacizumab) Biosimilars Sales Value Share by Region (2021-2026) Table 50. Global Avastin (Bevacizumab) Biosimilars Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Avastin (Bevacizumab) Biosimilars Sales Value Share by Region (2027-2032) Table 52. Global Avastin (Bevacizumab) Biosimilars Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Avastin (Bevacizumab) Biosimilars Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Avastin (Bevacizumab) Biosimilars Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Avastin (Bevacizumab) Biosimilars Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Avastin (Bevacizumab) Biosimilars Sales by Country (2021-2026) & (K Units) Table 57. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Country (2021-2026) Table 58. Global Avastin (Bevacizumab) Biosimilars Sales by Country (2027-2032) & (K Units) Table 59. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Country (2027-2032) Table 60. Global Avastin (Bevacizumab) Biosimilars Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Avastin (Bevacizumab) Biosimilars Sales Value Market Share by Country (2021-2026) Table 62. Global Avastin (Bevacizumab) Biosimilars Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Avastin (Bevacizumab) Biosimilars Sales Value Market Share by Country (2027-2032) Table 64. Biocad Company Information Table 65. Biocad Business Overview Table 66. Biocad Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Biocad Avastin (Bevacizumab) Biosimilars Product Portfolio Table 68. Biocad Recent Development Table 69. Biocon Company Information Table 70. Biocon Business Overview Table 71. Biocon Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Biocon Avastin (Bevacizumab) Biosimilars Product Portfolio Table 73. Biocon Recent Development Table 74. Cadila Pharmaceuticals Company Information Table 75. Cadila Pharmaceuticals Business Overview Table 76. Cadila Pharmaceuticals Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Cadila Pharmaceuticals Avastin (Bevacizumab) Biosimilars Product Portfolio Table 78. Cadila Pharmaceuticals Recent Development Table 79. Centus Company Information Table 80. Centus Business Overview Table 81. Centus Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Centus Avastin (Bevacizumab) Biosimilars Product Portfolio Table 83. Centus Recent Development Table 84. Dr Reddy's Company Information Table 85. Dr Reddy's Business Overview Table 86. Dr Reddy's Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Dr Reddy's Avastin (Bevacizumab) Biosimilars Product Portfolio Table 88. Dr Reddy's Recent Development Table 89. Genentech Company Information Table 90. Genentech Business Overview Table 91. Genentech Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Genentech Avastin (Bevacizumab) Biosimilars Product Portfolio Table 93. Genentech Recent Development Table 94. Hetero Company Information Table 95. Hetero Business Overview Table 96. Hetero Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Hetero Avastin (Bevacizumab) Biosimilars Product Portfolio Table 98. Hetero Recent Development Table 99. Kirin Biologics Company Information Table 100. Kirin Biologics Business Overview Table 101. Kirin Biologics Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Kirin Biologics Avastin (Bevacizumab) Biosimilars Product Portfolio Table 103. Kirin Biologics Recent Development Table 104. MAbxience Company Information Table 105. MAbxience Business Overview Table 106. MAbxience Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. MAbxience Avastin (Bevacizumab) Biosimilars Product Portfolio Table 108. MAbxience Recent Development Table 109. PharmaPraxis Company Information Table 110. PharmaPraxis Business Overview Table 111. PharmaPraxis Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. PharmaPraxis Avastin (Bevacizumab) Biosimilars Product Portfolio Table 113. PharmaPraxis Recent Development Table 114. PlantForm Company Information Table 115. PlantForm Business Overview Table 116. PlantForm Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. PlantForm Avastin (Bevacizumab) Biosimilars Product Portfolio Table 118. PlantForm Recent Development Table 119. Samsung Bioepis Company Information Table 120. Samsung Bioepis Business Overview Table 121. Samsung Bioepis Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Samsung Bioepis Avastin (Bevacizumab) Biosimilars Product Portfolio Table 123. Samsung Bioepis Recent Development Table 124. Sartorius Company Information Table 125. Sartorius Business Overview Table 126. Sartorius Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Sartorius Avastin (Bevacizumab) Biosimilars Product Portfolio Table 128. Sartorius Recent Development Table 129. Amgen Company Information Table 130. Amgen Business Overview Table 131. Amgen Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Amgen Avastin (Bevacizumab) Biosimilars Product Portfolio Table 133. Amgen Recent Development Table 134. BeiGene Company Information Table 135. BeiGene Business Overview Table 136. BeiGene Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. BeiGene Avastin (Bevacizumab) Biosimilars Product Portfolio Table 138. BeiGene Recent Development Table 139. Bayer Company Information Table 140. Bayer Business Overview Table 141. Bayer Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Bayer Avastin (Bevacizumab) Biosimilars Product Portfolio Table 143. Bayer Recent Development Table 144. TOT BIOPHARM Company Information Table 145. TOT BIOPHARM Business Overview Table 146. TOT BIOPHARM Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. TOT BIOPHARM Avastin (Bevacizumab) Biosimilars Product Portfolio Table 148. TOT BIOPHARM Recent Development Table 149. Henlius Company Information Table 150. Henlius Business Overview Table 151. Henlius Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Henlius Avastin (Bevacizumab) Biosimilars Product Portfolio Table 153. Henlius Recent Development Table 154. Pfizer Company Information Table 155. Pfizer Business Overview Table 156. Pfizer Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Pfizer Avastin (Bevacizumab) Biosimilars Product Portfolio Table 158. Pfizer Recent Development Table 159. Eli Lilly Company Information Table 160. Eli Lilly Business Overview Table 161. Eli Lilly Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. Eli Lilly Avastin (Bevacizumab) Biosimilars Product Portfolio Table 163. Eli Lilly Recent Development Table 164. Roche Company Information Table 165. Roche Business Overview Table 166. Roche Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 167. Roche Avastin (Bevacizumab) Biosimilars Product Portfolio Table 168. Roche Recent Development Table 169. Luye Pharmaceutical Company Information Table 170. Luye Pharmaceutical Business Overview Table 171. Luye Pharmaceutical Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 172. Luye Pharmaceutical Avastin (Bevacizumab) Biosimilars Product Portfolio Table 173. Luye Pharmaceutical Recent Development Table 174. Mylan Company Information Table 175. Mylan Business Overview Table 176. Mylan Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 177. Mylan Avastin (Bevacizumab) Biosimilars Product Portfolio Table 178. Mylan Recent Development Table 179. Qilu Pharmaceutical Company Information Table 180. Qilu Pharmaceutical Business Overview Table 181. Qilu Pharmaceutical Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 182. Qilu Pharmaceutical Avastin (Bevacizumab) Biosimilars Product Portfolio Table 183. Qilu Pharmaceutical Recent Development Table 184. Innovent Company Information Table 185. Innovent Business Overview Table 186. Innovent Avastin (Bevacizumab) Biosimilars Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 187. Innovent Avastin (Bevacizumab) Biosimilars Product Portfolio Table 188. Innovent Recent Development Table 189. Key Raw Materials Table 190. Raw Materials Key Suppliers Table 191. Avastin (Bevacizumab) Biosimilars Distributors List Table 192. Avastin (Bevacizumab) Biosimilars Customers List Table 193. Research Programs/Design for This Report Table 194. Authors List of This Report Table 195. Secondary Sources Table 196. Primary Sources List of Figures Figure 1. Avastin (Bevacizumab) Biosimilars Product Image Figure 2. Global Avastin (Bevacizumab) Biosimilars Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Avastin (Bevacizumab) Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 4. Global Avastin (Bevacizumab) Biosimilars Sales (2021-2032) & (K Units) Figure 5. Global Avastin (Bevacizumab) Biosimilars Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Avastin (Bevacizumab) Biosimilars Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Cancers Image Figure 10. AMD Image Figure 11. Global Avastin (Bevacizumab) Biosimilars Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Avastin (Bevacizumab) Biosimilars Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Avastin (Bevacizumab) Biosimilars Sales Volume Share by Type (2021-2032) Figure 14. Global Avastin (Bevacizumab) Biosimilars Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Avastin (Bevacizumab) Biosimilars Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Avastin (Bevacizumab) Biosimilars Sales Value Share by Type (2021-2032) Figure 17. Hospitals Image Figure 18. Clinics Image Figure 19. Others Image Figure 20. Global Avastin (Bevacizumab) Biosimilars Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Avastin (Bevacizumab) Biosimilars Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Avastin (Bevacizumab) Biosimilars Sales Volume Share by Application (2021-2032) Figure 23. Global Avastin (Bevacizumab) Biosimilars Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Avastin (Bevacizumab) Biosimilars Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Avastin (Bevacizumab) Biosimilars Sales Value Share by Application (2021-2032) Figure 26. Global Avastin (Bevacizumab) Biosimilars Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Avastin (Bevacizumab) Biosimilars Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Avastin (Bevacizumab) Biosimilars Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Avastin (Bevacizumab) Biosimilars Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Avastin (Bevacizumab) Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 31. North America Avastin (Bevacizumab) Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Avastin (Bevacizumab) Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Avastin (Bevacizumab) Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Avastin (Bevacizumab) Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Avastin (Bevacizumab) Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Avastin (Bevacizumab) Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 37. South America Avastin (Bevacizumab) Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Avastin (Bevacizumab) Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Avastin (Bevacizumab) Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Avastin (Bevacizumab) Biosimilars Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Avastin (Bevacizumab) Biosimilars Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Cancers
  • AMD
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Biocad
  • Biocon
  • Cadila Pharmaceuticals
  • Centus
  • Dr Reddy's
  • Genentech
  • Hetero
  • Kirin Biologics
  • MAbxience
  • PharmaPraxis
  • PlantForm
  • Samsung Bioepis
  • Sartorius
  • Amgen
  • BeiGene
  • Bayer
  • TOT BIOPHARM
  • Henlius
  • Pfizer
  • Eli Lilly
  • Roche
  • Luye Pharmaceutical
  • Mylan
  • Qilu Pharmaceutical
  • Innovent

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Avastin (Bevacizumab) Biosimilars Sales Value (2021-2032)
  4. 1.2.2 Global Avastin (Bevacizumab) Biosimilars Sales Volume (2021-2032)
  5. 1.2.3 Global Avastin (Bevacizumab) Biosimilars Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Avastin (Bevacizumab) Biosimilars Market Dynamics
  1. 2.1 Avastin (Bevacizumab) Biosimilars Industry Trends
  2. 2.2 Avastin (Bevacizumab) Biosimilars Industry Drivers
  3. 2.3 Avastin (Bevacizumab) Biosimilars Industry Opportunities and Challenges
  4. 2.4 Avastin (Bevacizumab) Biosimilars Industry Restraints
3 Avastin (Bevacizumab) Biosimilars Market by Company
  1. 3.1 Global Avastin (Bevacizumab) Biosimilars Company Revenue Ranking in 2025
  2. 3.2 Global Avastin (Bevacizumab) Biosimilars Revenue by Company (2021-2026)
  3. 3.3 Global Avastin (Bevacizumab) Biosimilars Sales Volume by Company (2021-2026)
  4. 3.4 Global Avastin (Bevacizumab) Biosimilars Average Price by Company (2021-2026)
  5. 3.5 Global Avastin (Bevacizumab) Biosimilars Company Ranking (2024-2026)
  6. 3.6 Global Avastin (Bevacizumab) Biosimilars Company Manufacturing Base and Headquarters
  7. 3.7 Global Avastin (Bevacizumab) Biosimilars Company Product Type and Application
  8. 3.8 Global Avastin (Bevacizumab) Biosimilars Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Avastin (Bevacizumab) Biosimilars Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Avastin (Bevacizumab) Biosimilars Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Avastin (Bevacizumab) Biosimilars Market by Type
  1. 4.1 Avastin (Bevacizumab) Biosimilars Type Introduction
  2. 4.1.1 Cancers
  3. 4.1.2 AMD
  4. 4.2 Global Avastin (Bevacizumab) Biosimilars Sales Volume by Type
  5. 4.2.1 Global Avastin (Bevacizumab) Biosimilars Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Avastin (Bevacizumab) Biosimilars Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Avastin (Bevacizumab) Biosimilars Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Avastin (Bevacizumab) Biosimilars Sales Value by Type
  9. 4.3.1 Global Avastin (Bevacizumab) Biosimilars Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Avastin (Bevacizumab) Biosimilars Sales Value by Type (2021-2032)
  11. 4.3.3 Global Avastin (Bevacizumab) Biosimilars Sales Value Share by Type (2021-2032)
5 Avastin (Bevacizumab) Biosimilars Market by Application
  1. 5.1 Avastin (Bevacizumab) Biosimilars Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Avastin (Bevacizumab) Biosimilars Sales Volume by Application
  6. 5.2.1 Global Avastin (Bevacizumab) Biosimilars Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Avastin (Bevacizumab) Biosimilars Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Avastin (Bevacizumab) Biosimilars Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Avastin (Bevacizumab) Biosimilars Sales Value by Application
  10. 5.3.1 Global Avastin (Bevacizumab) Biosimilars Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Avastin (Bevacizumab) Biosimilars Sales Value by Application (2021-2032)
  12. 5.3.3 Global Avastin (Bevacizumab) Biosimilars Sales Value Share by Application (2021-2032)
6 Avastin (Bevacizumab) Biosimilars Regional Sales and Value Analysis
  1. 6.1 Global Avastin (Bevacizumab) Biosimilars Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Avastin (Bevacizumab) Biosimilars Sales by Region (2021-2032)
  3. 6.2.1 Global Avastin (Bevacizumab) Biosimilars Sales by Region: 2021-2026
  4. 6.2.2 Global Avastin (Bevacizumab) Biosimilars Sales by Region (2027-2032)
  5. 6.3 Global Avastin (Bevacizumab) Biosimilars Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Avastin (Bevacizumab) Biosimilars Sales Value by Region (2021-2032)
  7. 6.4.1 Global Avastin (Bevacizumab) Biosimilars Sales Value by Region: 2021-2026
  8. 6.4.2 Global Avastin (Bevacizumab) Biosimilars Sales Value by Region (2027-2032)
  9. 6.5 Global Avastin (Bevacizumab) Biosimilars Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Avastin (Bevacizumab) Biosimilars Sales Value (2021-2032)
  12. 6.6.2 North America Avastin (Bevacizumab) Biosimilars Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Avastin (Bevacizumab) Biosimilars Sales Value (2021-2032)
  15. 6.7.2 Europe Avastin (Bevacizumab) Biosimilars Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Avastin (Bevacizumab) Biosimilars Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Avastin (Bevacizumab) Biosimilars Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Avastin (Bevacizumab) Biosimilars Sales Value (2021-2032)
  21. 6.9.2 South America Avastin (Bevacizumab) Biosimilars Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Avastin (Bevacizumab) Biosimilars Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Avastin (Bevacizumab) Biosimilars Sales Value Share by Country, 2025 VS 2032
7 Avastin (Bevacizumab) Biosimilars Country-level Sales and Value Analysis
  1. 7.1 Global Avastin (Bevacizumab) Biosimilars Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Avastin (Bevacizumab) Biosimilars Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Avastin (Bevacizumab) Biosimilars Sales by Country (2021-2032)
  4. 7.3.1 Global Avastin (Bevacizumab) Biosimilars Sales by Country (2021-2026)
  5. 7.3.2 Global Avastin (Bevacizumab) Biosimilars Sales by Country (2027-2032)
  6. 7.4 Global Avastin (Bevacizumab) Biosimilars Sales Value by Country (2021-2032)
  7. 7.4.1 Global Avastin (Bevacizumab) Biosimilars Sales Value by Country (2021-2026)
  8. 7.4.2 Global Avastin (Bevacizumab) Biosimilars Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Avastin (Bevacizumab) Biosimilars Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Avastin (Bevacizumab) Biosimilars Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Avastin (Bevacizumab) Biosimilars Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Biocad
  2. 8.1.1 Biocad Company Information
  3. 8.1.2 Biocad Business Overview
  4. 8.1.3 Biocad Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Biocad Avastin (Bevacizumab) Biosimilars Product Portfolio
  6. 8.1.5 Biocad Recent Developments
  7. 8.2 Biocon
  8. 8.2.1 Biocon Company Information
  9. 8.2.2 Biocon Business Overview
  10. 8.2.3 Biocon Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Biocon Avastin (Bevacizumab) Biosimilars Product Portfolio
  12. 8.2.5 Biocon Recent Developments
  13. 8.3 Cadila Pharmaceuticals
  14. 8.3.1 Cadila Pharmaceuticals Company Information
  15. 8.3.2 Cadila Pharmaceuticals Business Overview
  16. 8.3.3 Cadila Pharmaceuticals Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Cadila Pharmaceuticals Avastin (Bevacizumab) Biosimilars Product Portfolio
  18. 8.3.5 Cadila Pharmaceuticals Recent Developments
  19. 8.4 Centus
  20. 8.4.1 Centus Company Information
  21. 8.4.2 Centus Business Overview
  22. 8.4.3 Centus Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Centus Avastin (Bevacizumab) Biosimilars Product Portfolio
  24. 8.4.5 Centus Recent Developments
  25. 8.5 Dr Reddy's
  26. 8.5.1 Dr Reddy's Company Information
  27. 8.5.2 Dr Reddy's Business Overview
  28. 8.5.3 Dr Reddy's Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Dr Reddy's Avastin (Bevacizumab) Biosimilars Product Portfolio
  30. 8.5.5 Dr Reddy's Recent Developments
  31. 8.6 Genentech
  32. 8.6.1 Genentech Company Information
  33. 8.6.2 Genentech Business Overview
  34. 8.6.3 Genentech Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Genentech Avastin (Bevacizumab) Biosimilars Product Portfolio
  36. 8.6.5 Genentech Recent Developments
  37. 8.7 Hetero
  38. 8.7.1 Hetero Company Information
  39. 8.7.2 Hetero Business Overview
  40. 8.7.3 Hetero Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Hetero Avastin (Bevacizumab) Biosimilars Product Portfolio
  42. 8.7.5 Hetero Recent Developments
  43. 8.8 Kirin Biologics
  44. 8.8.1 Kirin Biologics Company Information
  45. 8.8.2 Kirin Biologics Business Overview
  46. 8.8.3 Kirin Biologics Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Kirin Biologics Avastin (Bevacizumab) Biosimilars Product Portfolio
  48. 8.8.5 Kirin Biologics Recent Developments
  49. 8.9 MAbxience
  50. 8.9.1 MAbxience Company Information
  51. 8.9.2 MAbxience Business Overview
  52. 8.9.3 MAbxience Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 MAbxience Avastin (Bevacizumab) Biosimilars Product Portfolio
  54. 8.9.5 MAbxience Recent Developments
  55. 8.10 PharmaPraxis
  56. 8.10.1 PharmaPraxis Company Information
  57. 8.10.2 PharmaPraxis Business Overview
  58. 8.10.3 PharmaPraxis Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 PharmaPraxis Avastin (Bevacizumab) Biosimilars Product Portfolio
  60. 8.10.5 PharmaPraxis Recent Developments
  61. 8.11 PlantForm
  62. 8.11.1 PlantForm Company Information
  63. 8.11.2 PlantForm Business Overview
  64. 8.11.3 PlantForm Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 PlantForm Avastin (Bevacizumab) Biosimilars Product Portfolio
  66. 8.11.5 PlantForm Recent Developments
  67. 8.12 Samsung Bioepis
  68. 8.12.1 Samsung Bioepis Company Information
  69. 8.12.2 Samsung Bioepis Business Overview
  70. 8.12.3 Samsung Bioepis Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Samsung Bioepis Avastin (Bevacizumab) Biosimilars Product Portfolio
  72. 8.12.5 Samsung Bioepis Recent Developments
  73. 8.13 Sartorius
  74. 8.13.1 Sartorius Company Information
  75. 8.13.2 Sartorius Business Overview
  76. 8.13.3 Sartorius Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Sartorius Avastin (Bevacizumab) Biosimilars Product Portfolio
  78. 8.13.5 Sartorius Recent Developments
  79. 8.14 Amgen
  80. 8.14.1 Amgen Company Information
  81. 8.14.2 Amgen Business Overview
  82. 8.14.3 Amgen Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Amgen Avastin (Bevacizumab) Biosimilars Product Portfolio
  84. 8.14.5 Amgen Recent Developments
  85. 8.15 BeiGene
  86. 8.15.1 BeiGene Company Information
  87. 8.15.2 BeiGene Business Overview
  88. 8.15.3 BeiGene Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 BeiGene Avastin (Bevacizumab) Biosimilars Product Portfolio
  90. 8.15.5 BeiGene Recent Developments
  91. 8.16 Bayer
  92. 8.16.1 Bayer Company Information
  93. 8.16.2 Bayer Business Overview
  94. 8.16.3 Bayer Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Bayer Avastin (Bevacizumab) Biosimilars Product Portfolio
  96. 8.16.5 Bayer Recent Developments
  97. 8.17 TOT BIOPHARM
  98. 8.17.1 TOT BIOPHARM Company Information
  99. 8.17.2 TOT BIOPHARM Business Overview
  100. 8.17.3 TOT BIOPHARM Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 TOT BIOPHARM Avastin (Bevacizumab) Biosimilars Product Portfolio
  102. 8.17.5 TOT BIOPHARM Recent Developments
  103. 8.18 Henlius
  104. 8.18.1 Henlius Company Information
  105. 8.18.2 Henlius Business Overview
  106. 8.18.3 Henlius Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Henlius Avastin (Bevacizumab) Biosimilars Product Portfolio
  108. 8.18.5 Henlius Recent Developments
  109. 8.19 Pfizer
  110. 8.19.1 Pfizer Company Information
  111. 8.19.2 Pfizer Business Overview
  112. 8.19.3 Pfizer Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Pfizer Avastin (Bevacizumab) Biosimilars Product Portfolio
  114. 8.19.5 Pfizer Recent Developments
  115. 8.20 Eli Lilly
  116. 8.20.1 Eli Lilly Company Information
  117. 8.20.2 Eli Lilly Business Overview
  118. 8.20.3 Eli Lilly Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Eli Lilly Avastin (Bevacizumab) Biosimilars Product Portfolio
  120. 8.20.5 Eli Lilly Recent Developments
  121. 8.21 Roche
  122. 8.21.1 Roche Company Information
  123. 8.21.2 Roche Business Overview
  124. 8.21.3 Roche Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Roche Avastin (Bevacizumab) Biosimilars Product Portfolio
  126. 8.21.5 Roche Recent Developments
  127. 8.22 Luye Pharmaceutical
  128. 8.22.1 Luye Pharmaceutical Company Information
  129. 8.22.2 Luye Pharmaceutical Business Overview
  130. 8.22.3 Luye Pharmaceutical Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Luye Pharmaceutical Avastin (Bevacizumab) Biosimilars Product Portfolio
  132. 8.22.5 Luye Pharmaceutical Recent Developments
  133. 8.23 Mylan
  134. 8.23.1 Mylan Company Information
  135. 8.23.2 Mylan Business Overview
  136. 8.23.3 Mylan Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 Mylan Avastin (Bevacizumab) Biosimilars Product Portfolio
  138. 8.23.5 Mylan Recent Developments
  139. 8.24 Qilu Pharmaceutical
  140. 8.24.1 Qilu Pharmaceutical Company Information
  141. 8.24.2 Qilu Pharmaceutical Business Overview
  142. 8.24.3 Qilu Pharmaceutical Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  143. 8.24.4 Qilu Pharmaceutical Avastin (Bevacizumab) Biosimilars Product Portfolio
  144. 8.24.5 Qilu Pharmaceutical Recent Developments
  145. 8.25 Innovent
  146. 8.25.1 Innovent Company Information
  147. 8.25.2 Innovent Business Overview
  148. 8.25.3 Innovent Avastin (Bevacizumab) Biosimilars Sales, Value and Gross Margin (2021-2026)
  149. 8.25.4 Innovent Avastin (Bevacizumab) Biosimilars Product Portfolio
  150. 8.25.5 Innovent Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Avastin (Bevacizumab) Biosimilars Value Chain Analysis
  2. 9.1.1 Avastin (Bevacizumab) Biosimilars Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Avastin (Bevacizumab) Biosimilars Sales Mode & Process
  6. 9.2 Avastin (Bevacizumab) Biosimilars Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Avastin (Bevacizumab) Biosimilars Distributors
  9. 9.2.3 Avastin (Bevacizumab) Biosimilars Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst